<![CDATA[Boehringer Ingelheim International GmbH 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=20742>Thu, 09 Apr 2026 06:37:16 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration]]>https://www.newswire.co.kr/newsRead.php?no=930281Fri, 10 Sep 2021 15:15:00 +0900<![CDATA[Boehringer Ingelheim and Gubra Join Forces to Identify and Validate Innovative Peptides for the Treatment of Obesity]]>https://www.newswire.co.kr/newsRead.php?no=919281Tue, 02 Mar 2021 15:05:32 +0900<![CDATA[Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies]]>https://www.newswire.co.kr/newsRead.php?no=917161Wed, 13 Jan 2021 09:40:41 +0900<![CDATA[Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D]]>https://www.newswire.co.kr/newsRead.php?no=917096Tue, 12 Jan 2021 11:49:32 +0900<![CDATA[New SARS-CoV-2 Neutralizing Antibody enters Clinical Phase]]>https://www.newswire.co.kr/newsRead.php?no=916278Mon, 21 Dec 2020 11:30:40 +0900<![CDATA[Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates]]>https://www.newswire.co.kr/newsRead.php?no=915746Fri, 11 Dec 2020 11:38:04 +0900<![CDATA[Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program]]>https://www.newswire.co.kr/newsRead.php?no=915660Thu, 10 Dec 2020 10:57:04 +0900<![CDATA[Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders - a Novel Approach to Fight Cancer]]>https://www.newswire.co.kr/newsRead.php?no=915469Tue, 08 Dec 2020 10:40:37 +0900<![CDATA[Empagliflozin reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial]]>https://www.newswire.co.kr/newsRead.php?no=914400Thu, 19 Nov 2020 13:31:33 +0900<![CDATA[Boehringer Ingelheim receives positive CHMP opinion for use of Pradaxa® (dabigatran etexilate) for the treatment and prevention of venous thromboembolic events in children from birth to less than 18 years of age]]>https://www.newswire.co.kr/newsRead.php?no=914184Mon, 16 Nov 2020 17:55:00 +0900<![CDATA[New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients[1]]]>https://www.newswire.co.kr/newsRead.php?no=913598Fri, 06 Nov 2020 09:45:36 +0900<![CDATA[Boehringer Ingelheim Begins Phase 2 Clinical Trial of a Targeted Therapy to Help People with Severe Respiratory Illness from COVID-19]]>https://www.newswire.co.kr/newsRead.php?no=913074Thu, 29 Oct 2020 10:25:00 +0900<![CDATA[Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic]]>https://www.newswire.co.kr/newsRead.php?no=912211Thu, 15 Oct 2020 11:49:29 +0900<![CDATA[Boehringer Ingelheim invests to further develop the pet care market in China]]>https://www.newswire.co.kr/newsRead.php?no=911516Tue, 29 Sep 2020 17:46:42 +0900<![CDATA[Phase II trial results demonstrated improvement in cognition with BI 425809 in adult patients with schizophrenia]]>https://www.newswire.co.kr/newsRead.php?no=910626Tue, 15 Sep 2020 11:12:53 +0900<![CDATA[Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia]]>https://www.newswire.co.kr/newsRead.php?no=910588Mon, 14 Sep 2020 11:11:44 +0900<![CDATA[Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers]]>https://www.newswire.co.kr/newsRead.php?no=910490Fri, 11 Sep 2020 08:46:22 +0900<![CDATA[Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 percent in adults with and without diabetes who had heart failure with reduced ejection fraction]]>https://www.newswire.co.kr/newsRead.php?no=909883Mon, 31 Aug 2020 09:07:43 +0900<![CDATA[Phase III InPedILD™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease]]>https://www.newswire.co.kr/newsRead.php?no=909191Thu, 13 Aug 2020 10:41:31 +0900<![CDATA[Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes]]>https://www.newswire.co.kr/newsRead.php?no=908639Fri, 31 Jul 2020 10:09:46 +0900<![CDATA[Boehringer Ingelheim acquires GST to strengthen its stem cell capabilities in Animal Health]]>https://www.newswire.co.kr/newsRead.php?no=908409Mon, 27 Jul 2020 17:33:53 +0900<![CDATA[European Commission approves third nintedanib indication in pulmonary fibrosis[1]]]>https://www.newswire.co.kr/newsRead.php?no=907918Thu, 16 Jul 2020 10:06:10 +0900<![CDATA[Perceived burden of disease is greater in younger people living with COPD, global survey reveals]]>https://www.newswire.co.kr/newsRead.php?no=907645Fri, 10 Jul 2020 10:27:58 +0900<![CDATA[Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases]]>https://www.newswire.co.kr/newsRead.php?no=907483Wed, 08 Jul 2020 08:53:46 +0900<![CDATA[New consortium EUbOPEN will provide tools to unlock disease biology]]>https://www.newswire.co.kr/newsRead.php?no=906068Tue, 09 Jun 2020 09:24:54 +0900